SCHEMBL3106599

SCHEMBL3106599

COc1cc(NC(CC(C)C)c2cc(-c3ccccc3)oc2C)ccc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.46
MAPT P10636 4/20 0.46
HPGD P15428 4/20 0.46
ABCC8 Q09428 1/20 0.42
HSD17B10 Q99714 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALOX12 P18054 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3094101 0.88 ALDH1A1 (0.43) ALDH1A1MAPTHPGDHSD17B10NPC1
SCHEMBL3094830 0.88 ALDH1A1 (0.43) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL3108079 0.87 ALDH1A1 (0.42) ALDH1A1MAPTHPGDNPC1RAB9A
SCHEMBL3107126 0.83 ALDH1A1 (0.47) ALDH1A1MAPTHPGDHSD17B10NPC1
SCHEMBL3101009 0.81 ALDH1A1 (0.41) ALDH1A1MAPTHPGDHSD17B10RAB9A
SCHEMBL3089967 0.79 PPARD (0.42) ALDH1A1MAPTHPGDHSD17B10NPC1
SCHEMBL3102029 0.78 PPARD (0.45) ALDH1A1MAPTHPGDNPC1SMN1; SMN2
SCHEMBL3101592 0.78 GCG (0.44) ALDH1A1MAPTHPGDKDM4EMEN1
SCHEMBL3110199 0.77 ALDH1A1 (0.41) ALDH1A1MAPTHPGDNPC1MEN1
SCHEMBL3109777 0.74 GCG (0.52) NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR ALDH1A1 3963/4885MAPT 4877/4885HPGD 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.